MOLECULIN BIOTECH INC

Insider CFO buy at $0.75 shows confidence amid Moleculin’s steep decline – see how insider moves could spark a rebound in the Annamycin program.

Insider buying by Moleculin Biotech’s Chief Science Officer signals confidence in its skin‑cancer pipeline and potential upcoming liquidity events. Click to learn how this tiny trade could shape the stock’s next move.